共 50 条
One year in review 2018: novelties in the treatment of rheumatoid arthritis
被引:1
|作者:
Bortoluzzi, A.
[1
]
Furini, F.
[1
]
Generali, E.
[2
]
Silvagni, E.
[1
]
Luciano, N.
[3
]
Scire, C. A.
[1
,4
]
机构:
[1] Univ Ferrara, Rheumatol Unit, Dept Med Sci, Ferrara, Italy
[2] Humanitas Clin & Res Ctr, Div Rheumatol & Clin Immunol, Milan, Italy
[3] Univ Pisa, Rheumatol Unit, Dept Clin & Expt Med, Pisa, Italy
[4] Italian Soc Rheumatol, Epidemiol Unit, Milan, Italy
关键词:
rheumatoid arthritis;
biologics;
treatment;
management;
TUMOR-NECROSIS-FACTOR;
MODIFYING ANTIRHEUMATIC DRUGS;
LONG-TERM EFFECTIVENESS;
RANDOMIZED PHASE IIB;
LOW DISEASE-ACTIVITY;
DOUBLE-BLIND;
OPEN-LABEL;
MONOCLONAL-ANTIBODY;
CLINICAL-OUTCOMES;
INADEQUATE RESPONSE;
D O I:
暂无
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
The current approach to treatment of rheumatoid arthritis (RA) includes early and aggressive intervention aiming to reach early and persistent low disease activity and remission. New drugs have improved the therapeutic armamentarium of rheumatologists, providing new options for patients. Beyond these innovations, new evidence has improved the safety of therapies and provided tools for the optimisation of long-term management of RA. This paper reviews the most relevant studies published over the last year in the field of treatment of RA.
引用
下载
收藏
页码:347 / 361
页数:15
相关论文